Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report

Docetaxel is the current first-line treatment for castration-resistant prostate cancer (CRPC), following failure to respond to maximal androgen blockade (MAB). Patients who fail to respond to docetaxel may receive cabazitaxel or abiraterone; however, there are no recommendations on which of these tw...

Descripción completa

Detalles Bibliográficos
Autores principales: MARECH, ILARIA, VACCA, ANGELO, SIVESTRIS, NICOLA, GNONI, ANTONIO, LORUSSO, VITO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701088/
https://www.ncbi.nlm.nih.gov/pubmed/23833660
http://dx.doi.org/10.3892/ol.2013.1275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701088/
https://www.ncbi.nlm.nih.gov/pubmed/23833660
http://dx.doi.org/10.3892/ol.2013.1275

Ejemplares similares